Vascular damage from repeated injection causes local ischemia and thrombophlebitis
Impaired immune function from malnutrition, HIV, and opioid immunosuppression amplifies infection risk
Therapeutic Considerations
Harm reduction framework
Needle and syringe exchange programs reduce HIV and HCV transmission (ACEP Level B)
Naloxone distribution: patients and contacts should receive naloxone training and supply
Naloxone 4 mg intranasal (Narcan) or 2 mg/0.4 ml prefilled autoinjector
Safe injection site referral where legally available
Evidence base for OUD pharmacotherapy
Buprenorphine: Class I recommendation for OUD treatment (ASAM, SAMHSA guidelines)
Reduces overdose mortality by 50–70% (Blanco & Volkow, Lancet 2019)
Hospital-initiated buprenorphine improves treatment retention at 30 days vs. referral alone
Methadone: Class I recommendation; reduces illicit opioid use and criminal activity
Requires enrollment in federally licensed OTP for outpatient dispensing in US
Naltrexone: effective for motivated opioid-free patients; monthly extended-release injection preferred
Vivitrol 380 mg IM monthly; requires 7–10 opioid-free days to avoid precipitated withdrawal
Antibiotic stewardship considerations
Culture-directed therapy on sensitivity results to narrow empiric broad-spectrum coverage
Clindamycin added specifically for toxin suppression in GAS necrotizing infection (Class IIa)
Minimum antibiotic duration for osteomyelitis: 4–6 weeks; endocarditis: 6 weeks
Oral step-down antibiotic therapy acceptable in osteomyelitis after 1 week IV if sensitive organism and good GI absorption (OVIVA trial, NEJM 2019)
Patient Discharge Instructions
copy discharge instructions
Wound care instructions
Keep all wounds clean and dry; change dressings as instructed by your wound care nurse
Do not pick at or probe wounds — this increases infection risk
Watch for signs of worsening infection at wound sites
Return to ER immediately for: increasing redness, swelling, warmth, or pain at wound
Return immediately for: new skin color changes (green, black, purple) spreading from wound
Return immediately for: foul-smelling drainage or pus from wound
Opioid use disorder treatment instructions
Take buprenorphine/naloxone exactly as prescribed — do not miss doses
Buprenorphine is a medication that treats opioid use disorder and prevents withdrawal
Your prescription: buprenorphine/naloxone (Suboxone) dose as prescribed, placed under your tongue to dissolve
Do not use krokodil or other street opioids while taking buprenorphine — serious harm can result
Contact your addiction medicine follow-up clinic within 1 week of discharge
Infection warning signs — return immediately for
Fever (temperature > 38 C) or chills
New shortness of breath or chest pain
Jaw pain, jaw swelling, or exposed bone in your mouth
Double vision, difficulty swallowing, or slurred speech (nerve problem — call 911)
Feeling confused or unusually drowsy
Inability to eat or drink due to nausea and vomiting
Safe use and harm reduction
Krokodil causes severe, permanent tissue damage and organ failure — there is no safe dose
Average survival with continued krokodil use is estimated at 1–3 years
If you cannot stop, please use sterile needles every time — never share needles, cookers, or water
Naloxone (Narcan) has been given to you — keep it with you and teach someone how to use it
Local needle exchange and harm reduction program contact: connect with your social worker before discharge
Follow-up appointments
Wound recheck within 48–72 hours of discharge
Addiction medicine or opioid treatment program within 1 week
Infectious disease clinic within 1–2 weeks (for HIV, HCV, or other bloodborne infection results)
Oral surgery (jaw specialist) if you had jaw problems — call the number given to you before discharge
References
Guidelines and key sources
Alves EA et al. DARK Classics in Chemical Neuroscience: Krokodil. ACS Chemical Neuroscience. 2020. PMID: 32877160
Comprehensive review of desomorphine chemistry, pharmacology, and tissue toxicity mechanisms
Alves EA et al. The Harmful Chemistry Behind Krokodil (Desomorphine) Synthesis and Mechanisms of Toxicity. Forensic Science International. 2015. PMID: 25710781
Street synthesis analysis and contaminant identification
Grund JP, Latypov A, Harris M. Breaking Worse: The Emergence of Krokodil and Excessive Injuries Among People Who Inject Drugs in Eurasia. International Journal on Drug Policy. 2013. PMID: 23726898
Epidemiologic emergence, geographic spread, and harm profile
Booth RE et al. Krokodile Injectors in Ukraine: Fueling the HIV Epidemic? AIDS and Behavior. 2016. PMID: 26033290
HIV risk amplification in krokodil-injecting populations
McDermott J et al. Necrotizing Soft Tissue Infections: A Review. JAMA Surgery. 2024
Comprehensive NSTI management including diagnosis, surgical approach, and antibiotic selection
Hua C et al. Necrotising Soft-Tissue Infections. Lancet Infectious Diseases. 2023. PMID: 36252579
Evidence-based NSTI pathogenesis and treatment
MacLeod CS et al. Predicting Necrotising Soft Tissue Infections in People Who Inject Drugs. International Journal of Surgery. 2023. PMID: 37042577
LRINEC poor performance in IDU; novel predictive nomogram
Rich KM, Solomon DA. Medical Complications of Injection Drug Use — Part I. NEJM Evidence. 2023
Systematic review of SSTI, endocarditis, and other IDU complications
Harris MTH et al. Medications for Opioid Use Disorder, Opioid Withdrawal, and Opioid Overdose. JAMA. 2026
Current pharmacotherapy evidence for OUD including buprenorphine and methadone
Weimer MB et al. ASAM Clinical Considerations: Buprenorphine Treatment of OUD for High-Potency Synthetic Opioids. Journal of Addiction Medicine. 2023
Low-dose buprenorphine induction (Bernese method) and COWS-guided initiation
Hatten BW et al. Clinical Policy: Critical Issues Related to Opioids in Adult Patients Presenting to the Emergency Department. Annals of Emergency Medicine. 2020
ACEP clinical policy on opioid use disorder management in the ED
Blanco C, Volkow ND. Management of Opioid Use Disorder in the USA: Present Status and Future Directions. Lancet. 2019. PMID: 30878228
Evidence base for buprenorphine and methadone mortality reduction (50–70%)
Winborn J, Kerrigan S. Desomorphine Screening Using Commercial Enzyme-Linked Immunosorbent Assays. Journal of Analytical Toxicology. 2017. PMID: 28369523
Cross-reactivity data for UDS detection of desomorphine (2.5–77%)
Marks LR et al. Infectious Complications of Injection Drug Use. Medical Clinics of North America. 2022. PMID: 34823730
van Kempen EEJ, Brand HS. Effects of Krokodil (Desomorphine) Use on Oral Health. British Dental Journal. 2019. PMID: 31705099
Systematic review of jaw osteonecrosis and oral complications
Florez DH et al. Desomorphine (Krokodil): An Overview of Its Chemistry, Pharmacology, Metabolism, Toxicology and Analysis. Drug and Alcohol Dependence. 2017. PMID: 28199917
Pharmacokinetics, half-life, CYP metabolism, and analytical detection methods
SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.